XT
ALLO icon

XTX Topco’s Allogene Therapeutics ALLO Stock Holding History

XTX Topco’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.3K Sell
30,923
-284,820
-90% -$625K ﹤0.01% 3651
2026
Q1 		$770K Sell
315,743
-160,564
-34% -$322K 0.01% 1643
2025
Q4 		$653K Sell
476,307
-297,896
-38% -$393K 0.02% 1375
2025
Q3 		$960K Buy
774,203
+746,431
+2,688% +$890K 0.05% 598
2025
Q2 		$31.4K Buy
27,772
+7,026
+34% +$9.34K ﹤0.01% 2098
2025
Q1 		$30.3K Sell
20,746
-137,791
-87% -$260K ﹤0.01% 2078
2024
Q4 		$338K Buy
+158,537
New +$391K 0.03% 1116
2024
Q2 		– Sell
-35,765
Closed -$160K – 1822
2024
Q1 		$160K Buy
35,765
+379
+1% +$1.58K 0.02% 1245
2023
Q4 		$114K Sell
35,386
-38,604
-52% -$109K 0.02% 1102
2023
Q3 		$235K Buy
73,990
+28,159
+61% +$123K 0.04% 916
2023
Q2 		$228K Buy
45,831
+259
+0.6% +$1.4K 0.04% 923
2023
Q1 		$225K Sell
45,572
-71,264
-61% -$457K 0.05% 865
2022
Q4 		$735K Buy
116,836
+78,194
+202% +$724K 0.16% 158
2022
Q3 		$417K Buy
+38,642
New +$525K 0.1% 319

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

XTX Topco's ALLO Position: Q2 2026 in Review

XTX Topco reduced its Allogene Therapeutics (ALLO) stake by 90% in Q2 2026, selling an estimated $625K and leaving 30,923 shares worth $64.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3651.

XTX Topco first reported a position in ALLO in Q3 2022 and has held it in 14 quarters since. The position peaked at $960K in Q3 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • XTX Topco held 30,923 shares of Allogene Therapeutics worth $64.3K as of Q2 2026.
  • XTX Topco sold 284,820 Allogene Therapeutics shares in Q2 2026, an estimated $625K.
  • Allogene Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3651 holding.
  • XTX Topco first reported a position in Allogene Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • XTX Topco's Allogene Therapeutics position peaked at $960K in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.